Literature DB >> 32675747

Late Sodium Current in Atrial Cardiomyocytes Contributes to the Induced and Spontaneous Atrial Fibrillation in Rabbit Hearts.

Yanpeng Chu1, Qiaomei Yang1, Lu Ren1, Shandong Yu1, Zhipei Liu2, Ying Chen1, Xiaohong Wei1, Sihui Huang1, Lv Song2, Peihua Zhang2, Jihua Ma2, Lin Wu1,3.   

Abstract

Increased late sodium current (INa) induces long QT syndrome 3 with increased risk of atrial fibrillation (AF). The role of atrial late INa in the induction of AF and in the treatment of AF was determined in this study. AF parameters were measured in isolated rabbit hearts exposed to late INa enhancer and inhibitors. Late INa from isolated atrial and ventricular myocytes were measured using whole-cell patch-clamp techniques. We found that induced-AF by programmed S1S2 stimulation and spontaneous episodes of AF were recorded in hearts exposed to either low (0.1-3 nM) or high (3-10 nM) concentrations of ATX-II (n = 10). Prolongations in atrial monophasic action potential duration at 90% completion of repolarization and effective refractory period by ATX-II (0.1-15 nM) were greater in hearts paced at slow than at fast rates (n = 5-10, P < 0.05). Both endogenous and ATX-II-enhanced late INa density were greater in atrial than that in ventricular myocytes (n = 9 and 8, P < 0.05). Eleclazine and ranolazine reduced AF window and AF burden in association with the inhibition of both endogenous and enhanced atrial late INa with half maximal inhibitory concentrations (IC50) of 1.14 and 9.78, and 0.94 and 8.31 μM, respectively. The IC50s for eleclazine and ranolazine to inhibit peak INa were 20.67 and 101.79 μM, respectively, in atrial myocytes. In conclusion, enhanced late INa in atrial myocytes increases the susceptibility for AF. Inhibition of either endogenous or enhanced late INa, with increased atrial potency of drugs is feasible for the treatment of AF.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32675747     DOI: 10.1097/FJC.0000000000000883

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

1.  Moricizine prevents atrial fibrillation by late sodium current inhibition in atrial myocytes.

Authors:  Tian Zou; Qingxing Chen; Chaofeng Chen; Guijian Liu; Yunlong Ling; Yang Pang; Ye Xu; Kuan Cheng; Wenqing Zhu; Ru-Xing Wang; Ling-Ling Qian; Junbo Ge
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

2.  Study on the role and mechanism of lncRNA in the remodeling of atrial energy metabolism in rabbits with atrial fibrillation based on nano sensor technology.

Authors:  Weifeng Jiang; Ming Xu; Mu Qin; Daoliang Zhang; Shaohui Wu; Xu Liu; Yu Zhang
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

Review 3.  Research Progress on Natural Products' Therapeutic Effects on Atrial Fibrillation by Regulating Ion Channels.

Authors:  Jinshan He; Sicong Li; Yumeng Ding; Yujia Tong; Xuebin Li
Journal:  Cardiovasc Ther       Date:  2022-03-22       Impact factor: 3.023

Review 4.  Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations.

Authors:  Dimitrios A Vrachatis; Konstantinos A Papathanasiou; Konstantinos E Iliodromitis; Sotiria G Giotaki; Charalampos Kossyvakis; Konstantinos Raisakis; Andreas Kaoukis; Vaia Lambadiari; Dimitrios Avramides; Bernhard Reimers; Giulio G Stefanini; Michael Cleman; Georgios Giannopoulos; Alexandra Lansky; Spyridon G Deftereos
Journal:  Drugs       Date:  2021-07-23       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.